Active cure trials rise as AI infrastructure accelerates
LISTEN
Direct audio file (MP3)Global active cure-related trials now total 21,353, with 48 new Wire signals and 27 new Cure research items added in the last 24h—an unusually busy pipeline from therapy to trials to translation. In cancer specifically, Merck and Moderna are signaling “a lot of exploring to do” after initial cancer vaccine success, while Verastem reports promising early multi-arm clinical results for its KRAS G12D inhibitor tested in 200+ patients with advanced solid tumors. The parallel capital/AI phase keeps tightening: policy makers and buyers are moving into model-driven workflows (e.g., Senate readiness of Claude for staffers) and infrastructure expansion (e.g., data center tax-break proposals), which matters because it changes how fast research, drafting, and operations can scale. Evidence is converting into influence in real time, but sustained clinical follow-through will decide whether today’s signals become durable cures—The window is still open.
Meta launched Muse Spark Open, claiming improved multi-step reasoning and software engineering versus Chinese competitors.
Faster open-weight reasoning and engineering cycles can accelerate how quickly teams turn medical hypotheses into testable systems, changing the pace of the cure race.
Watch for how Merck/Moderna pair ongoing cancer vaccine work with follow-on strategies, and track whether KRAS-directed early promise progresses beyond early results—time pressure remains high.